Business Segment Information

9 Months Ended

Jun. 30, 2015

Business Segment Information [Abstract]

Business Segment Information [Text Block]

Note 10.  Business Segment Information

The Company is organized based upon the products and services it provides to its customers.  The Company’s operations are comprised of the Pharmaceutical Distribution reportable segment and Other.  The Pharmaceutical Distribution reportable segment consists of the AmerisourceBergen Drug Corporation (“ABDC”) and AmerisourceBergen Specialty Group (“ABSG”) operating segments.  Other consists of the AmerisourceBergen Consulting Services (“ABCS”), World Courier Group, Inc. (“World Courier”), and MWI Veterinary Supply, Inc. (“MWI”) operating segments.

The following tables illustrate reportable segment information for the three and nine months ended June 30, 2015 and 2014 (in thousands):

	Revenue
	Three months ended						Nine months ended
	June 30,						June 30,
	2015			2014			2015			2014
Pharmaceutical Distribution	$	32,758,828		$	29,812,837		$	97,504,075		$	86,367,923
Other	1,532,907			620,275			3,214,977			1,796,910
Intersegment eliminations	(58,179		)	(84,958		)	(227,627		)	(184,414		)
Revenue	$	34,233,556		$	30,348,154		$	100,491,425		$	87,980,419

Intersegment eliminations primarily represent the elimination of certain ABCS sales to the Pharmaceutical Distribution reportable segment.

	Segment Operating Income
	Three months ended				Nine months ended
	June 30,				June 30,
	2015		2014		2015		2014
Pharmaceutical Distribution	$	377,771	$	359,795	$	1,256,747	$	1,019,506
Other	77,372		33,678		186,688		113,261
Total segment operating income	$	455,143	$	393,473	$	1,443,435	$	1,132,767

The following table reconciles total segment operating income to income (loss) from continuing operations before income taxes (in thousands):

	Income (Loss) From Continuing
	Operations Before Income Taxes
	Three months ended						Nine months ended
	June 30,						June 30,
	2015			2014			2015			2014
Total segment operating income	$	455,143		$	393,473		$	1,443,435		$	1,132,767
Gains on antitrust litigation settlements	43,567			2,524			65,050			24,396
LIFO expense	(158,710		)	(133,237		)	(453,878		)	(293,647		)
Acquisition related intangibles amortization	(19,710		)	(5,701		)	(34,478		)	(17,484		)
Warrant expense	14,900			(145,040		)	(1,109,211		)	(267,000		)
Employee severance, litigation and other	(2,625		)	(1,142		)	(30,999		)	(7,411		)
Operating income (loss)	332,565			110,877			(120,081		)	571,621
Other (income) loss	(1,534		)	(1,312		)	11,185			(5,692		)
Interest expense, net	29,793			20,903			70,081			59,209
Loss on early retirement of debt	—			32,954			—			32,954
Income (loss) from continuing operations before income taxes	$	304,306		$	58,332		$	(201,347	)	$	485,150

Segment operating income is evaluated by the chief operating decision maker of the Company before gains on antitrust litigation settlements; LIFO expense; acquisition related intangibles amortization; Warrant expense; employee severance, litigation and other; other (income) loss; interest expense, net; and loss on early retirement of debt.  All corporate office expenses are allocated to each operating segment.